Performance Nutrition's KidsPlex, Jr. ADD treatment claims draw FDA warning letter.
This article was originally published in The Tan Sheet
Executive Summary
PERFORMANCE NUTRITION KIDSPLEX, JR. ADD/ADHD CLAIMS DRAW WARNING LETTER from FDA to the Dallas-based nutritional supplements distributor. In the Dec. 4 letter, FDA takes aim at "objectionable" Performance Nutrition claims that make KidsPlex, Jr. an unapproved new drug. The claims include: "KidsPlex, Jr., because of its fortification with inhibitory amino acids, has the potential to help children with Attention Deficit Hyperactivity Disorder."